Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Toronto-Dominion Bank (TD) vs 10X Genomics Inc (TXG) Price & Performance

Toronto-Dominion BankTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Toronto-Dominion Bank vs 10X Genomics Inc — how do they compare? Toronto-Dominion Bank trades at $121.35 (market cap $199.91B), while 10X Genomics Inc trades at $58.76 (market cap $7.64B). The key difference: Toronto-Dominion Bank is far larger — about 26.2× 10X Genomics Inc's market cap, and Toronto-Dominion Bank pays a 2.64% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

TDTXG
Market Cap
$199.91B$7.64B
Sector
FinancialsHealth
52-Week High
$124.80$58.57
52-Week Low
$72.85$11.34
Dividend Yield
2.64%
Enterprise Value
$7.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Toronto-Dominion Bank

TD stock trades at $121.31, up 0.11% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.74, exceeding the $1.63 estimate, and maintains a strong net income margin of 23.38%. Analyst consensus is positive with 9 buy ratings and no sell ratings among 17 analysts. Recent news highlights value comparisons with peers and dividend stability.

Outlook remains favorable due to consistent earnings performance and robust profitability, though risks include high debt levels and potential regulatory scrutiny. The stock's valuation at a P/E of 19.95 is reasonable relative to historical margins, supporting a cautious bullish view for long-term investors seeking dividend income and steady growth.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

About Toronto-Dominion Bank

Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.

Read more on TD

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG